ClinicalTrials.gg
RecruitingNCT07448818Dynamic and IsUpdated May 1, 2026

Dynamic and Isometric Strength Training in Older Adults With Hypertension

An interventional study of Dynamic Strength Training and Isometric Strength Training in Hypertension and Elderly (People Aged 65 or More), sponsored by Raphael Mendes Ritti Dias. Recruiting at 1 site in Brazil. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Raphael Mendes Ritti Dias · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Hypertension with a site in Brazil — 28 open to participants now, 33 under way, 6 of them phase 3. Hypertension · Brazil.

Planned enrollment
107th of 189
60 · median 80
Started
2026
with 7 others
No phase
112 of 209
15 open now
Primary completion
2027-06
later than 20 of 32 live
Registered
203rd of 209
by date

Among the 209 studies in Hypertension with a site in Brazil, this one is the 107th largest by planned enrollment of the 189 interventional ones that give a count, is one of 8 that started in 2026, is one of 112 with no phase, reaches primary completion later than 20 of the 32 other live ones, and was the 203rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

28 of the 209 studies in Hypertension with a site in Brazil are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Hypertension with a site in Brazil, or all of them as a file.
02

Study summary

This feasibility study aims to evaluate the effects of dynamic strength training and isometric strength training on cardiovascular health indicators, mental health, and neuromuscular fitness in older adults with hypertension. Participants will be randomly assigned to one of the two training modalities and will complete supervised exercise sessions throughout the intervention period. The study will provide preliminary evidence regarding the safety, acceptability, and potential impact of each training modality on health outcomes in this population.

03

Conditions studied

  • Hypertension
  • Elderly (People Aged 65 or More)

Browse trials for

Keywords

  • Hypertension
  • Strength training
  • Resistance training
  • Cardiovascular health
  • blood pressure
  • old age
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of arterial hypertension and currently taking antihypertensive medication
  • Age 60 years or older
  • Resting blood pressure below 160/95 mmHg
  • No high cardiovascular risk according to the American College of Sports Medicine criteria (for participants with type 2 diabetes, glycemic control with fasting glucose \<100 mg/dL and postprandial glucose \<140 mg/dL)
  • Not participating in a structured exercise program for more than three months
  • No cognitive or functional limitations that prevent participation in the exercise program

Exclusion criteria

Exclusion Criteria

  • Presence of acute illnesses, such as influenza, sinusitis, gastroenteritis, urinary tract infection, fever, inflammatory processes, or any clinical condition requiring rest or that may compromise safety during assessments or training.
  • Decompensated clinical conditions, including: Blood pressure spikes, Chest pain, Uncontrolled arrhythmias, Shortness of breath at rest, Asthma exacerbations, Decompensated diabetes mellitus, characterized by Persistently elevated blood glucose levels (fasting glucose > 180 mg/dL or postprandial glucose > 250 mg/dL)
  • Irregular use of medication
  • Any unstable clinical condition or condition that represents additional risk for the practice of physical exercise.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Dynamic Strength Training

    The subjects randomized to this group will perform two supervised dynamic strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.

    Behavioral: Dynamic Strength Training

  • Experimental
    Isometric Strength Training

    The subjects randomized to this group will perform two supervised isometric strength training sessions per week for 6 weeks, each session lasting approximately 30 minutes.

    Behavioral: Isometric Strength Training

  • Other
    Control

    No supervised training will be provided. Participants in this group will not receive any exercise intervention during the 6-week study period, but they will be stimulated to be active.

    Behavioral: No supervised intervention Control

Interventions

  • BehavioralDynamic Strength Training

    The experimental group will perform dynamic strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group movements, initially 2 sets of 15 repetitions (Borg 4-6), progressing to 3 sets of 10 repetitions (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.

  • BehavioralIsometric Strength Training

    The experimental group will perform isometric strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group contractions, initially 2 sets of 60 seconds (Borg 4-6), progressing to 3 sets of 40 seconds (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.

  • BehavioralNo supervised intervention Control

    This group serves as a control and will not perform any structured exercise program.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Proportion of enrolled participants relative to the total number of eligible individuals contacted. Reported as a percentage.

    Time frame: Baseline and 6 weeks

  2. Adherence to training sessions

    Percentage of completed training sessions relative to the total number of planned sessions over the 6-week intervention period.

    Time frame: During 6 weeks

  3. Retention rate

    Proportion of participants who complete the full 6-week intervention

    Time frame: During 6 weeks

  4. Fidelity to exercise protocol

    Percentage of exercises performed according to the prescribed protocol parameters, including load, repetitions, and time under tension.

    Time frame: Duiring 6 weeks

  5. Acceptability of the intervention

    Acceptability assessed through a structured satisfaction questionnaire, scored from 0 to 10, administered at the end of the 6-week intervention

    Time frame: During 6 weeks

  6. Occurrence of adverse events

    Number of intervention-related adverse events, classified as mild, moderate, or severe

    Time frame: During 6 weeks

Secondary outcomes

  1. Change from baseline in Clinical resting blood pressure at 6 weeks

    Systolic and diastolic blood pressure measured with automatic device (HEM-742, Omron Healthcare, Japan) in seated position, average of last two of three readings, in millimeters of mercury.

    Time frame: Baseline and 6 weeks

  2. Change from baseline in Home blood pressure monitoring at 6 weeks

    Seven-day home monitoring with automatic device (Omron Healthcare, Japan), two readings morning and evening in duplicate; average of valid readings, in millimeters of mercury

    Time frame: Baseline and 6 weeks

  3. Change from baseline in Flow-mediated dilation at 6 weeks

    Brachial and femoral artery vasodilation assessed by ultrasonography with spectral Doppler (Cannon Xario, Japan); calculated as percentage change from baseline

    Time frame: Baseline and 6 weeks

  4. Change from baseline in Standard deviation of normal R-R intervals at 6 weeks

    Standard deviation of normal R-R intervals will be assessed using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).

    Time frame: Baseline and 6 weeks

  5. Change from baseline in Arterial stiffness at 6 weeks

    Carotid-femoral pulse wave velocity measured by applanation tonometry (SphygmoCor, AtCor Medical, Australia), calculated as distance/time in meters per second

    Time frame: Baseline and 6 weeks

  6. Change from baseline in Depressive symptoms at 6 weeks

    Geriatric Depression Scale (GDS-15), 15 items, scored 0-15, higher score = worse symptoms

    Time frame: Baseline and 6 weeks

  7. Change from baseline in Anxiety symptoms at 6 weeks

    Generalized Anxiety Disorder questionnaire (GAD-7), 7 items, scored 0-21, higher score = worse symptoms

    Time frame: Baseline and 6 weeks

  8. Change from baseline in Six-Minute Walk Test distance at 6 weeks

    Distance walked in meters during the six-minute walk test performed in a 30-meter corridor.

    Time frame: Baseline and 6 weeks

  9. Change from baseline in Root mean square of successive differences between R-R intervals at 6 weeks

    Root mean square of successive differences between R-R intervals will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).

    Time frame: Baseline to 6 weeks

  10. Change from baseline in Proportion of successive R-R intervals differing by more than 50 milliseconds at 6 weeks

    Proportion of successive R-R intervals differing by more than 50 milliseconds will be measured using the Polar V800 heart rate monitor (Polar Electro, Finland) and expressed in milliseconds (ms).

    Time frame: Baseline to 6 weeks.

  11. Change from baseline in Low-frequency spectral power at 6 weeks

    Low-frequency spectral power will be assessed using the Polar V800 (Polar Electro, Finland) and expressed in ms².

    Time frame: Baseline to 6 weeks.

  12. Change from baseline in high-frequency power at 6 weeks

    high-frequency power High-frequency component measured with Polar V800 (Polar Electro, Finland), expressed in ms².

    Time frame: Baseline to 6 weeks.

  13. Change from baseline in Low-frequency to high-frequency ratio at 6 weeks

    Low-frequency to high-frequency ratio measured with Polar V800 (Polar Electro, Finland).

    Time frame: Baseline to 6 weeks.

  14. Change from baseline in Timed Up and Go Time at 6 weeks

    time in seconds to stand from a chair, walk 3 meters, turn, return, and sit down.

    Time frame: Baseline and 6 weeks.

  15. Change from baseline in 30-second Chair stand repetitions at 6 weeks

    number of full stands from a seated position completed in 30seconds.

    Time frame: Baseline and 6 weeks.

  16. Change from baseline in handgrip strength at 6 weeks

    maximum voluntary isometric handgrip strength measured using handheld dynamometer instrutherm DM-90 (Brazil), expressed in kilogram-force (kgf).

    Time frame: Baseline and 6 weeks.

  17. Change from baseline in isometric knee extensor strength at 6 weeks

    Maximum isometric knee extensor strength measured at 90º knee angle using horizontal leg press, expressed in kilogram-force (kgf).

    Time frame: Baseline and 6 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be anonymized and shared after the completion of the study and publication of the main results

Supporting information: Study protocol

Time frame: Data will be shared adter the publication of the main trial

Access criteria: Will be avaliable in open repositories

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 4, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448818
Lead sponsor
Raphael Mendes Ritti Dias
Responsible party
Raphael Mendes Ritti Dias (PhD, University of Nove de Julho) — Sponsor-investigator
First posted
Mar 4, 2026
Start date
Mar 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Adão Luis Monte L Monte, Ms
Contact
adaoluiz8@outlook.com
+55 11 94666 5213
Raphael M Ritti-Dias, PhD
Contact
raphaelritti@gmail.com
+5519999406878
Raphael M Ritti-Dias, PhD
study chair · University of Nove de Julho

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion